Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

64 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Discovery of (S)-6-(3-cyclopentyl-2-(4-(trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic acid as a hepatoselective glucokinase activator clinical candidate for treating type 2 diabetes mellitus.
Pfefferkorn JA, Guzman-Perez A, Litchfield J, Aiello R, Treadway JL, Pettersen J, Minich ML, Filipski KJ, Jones CS, Tu M, Aspnes G, Risley H, Bian J, Stevens BD, Bourassa P, D'Aquila T, Baker L, Barucci N, Robertson AS, Bourbonais F, Derksen DR, Macdougall M, Cabrera O, Chen J, Lapworth AL, Landro JA, Zavadoski WJ, Atkinson K, Haddish-Berhane N, Tan B, Yao L, Kosa RE, Varma MV, Feng B, Duignan DB, El-Kattan A, Murdande S, Liu S, Ammirati M, Knafels J, Dasilva-Jardine P, Sweet L, Liras S, Rolph TP. Pfefferkorn JA, et al. Among authors: bourassa p. J Med Chem. 2012 Feb 9;55(3):1318-33. doi: 10.1021/jm2014887. Epub 2012 Jan 24. J Med Chem. 2012. PMID: 22196621
The design and synthesis of indazole and pyrazolopyridine based glucokinase activators for the treatment of type 2 diabetes mellitus.
Pfefferkorn JA, Tu M, Filipski KJ, Guzman-Perez A, Bian J, Aspnes GE, Sammons MF, Song W, Li JC, Jones CS, Patel L, Rasmusson T, Zeng D, Karki K, Hamilton M, Hank R, Atkinson K, Litchfield J, Aiello R, Baker L, Barucci N, Bourassa P, Bourbonais F, D'Aquila T, Derksen DR, MacDougall M, Robertson A. Pfefferkorn JA, et al. Among authors: bourassa p. Bioorg Med Chem Lett. 2012 Dec 1;22(23):7100-5. doi: 10.1016/j.bmcl.2012.09.082. Epub 2012 Sep 29. Bioorg Med Chem Lett. 2012. PMID: 23089526
Discovery of spirocyclic proline tryptophan hydroxylase-1 inhibitors.
Goldberg DR, De Lombaert S, Aiello R, Bourassa P, Barucci N, Zhang Q, Paralkar V, Valentine J, Zavadoski W. Goldberg DR, et al. Among authors: bourassa p. Bioorg Med Chem Lett. 2016 Feb 15;26(4):1124-9. doi: 10.1016/j.bmcl.2016.01.064. Epub 2016 Jan 22. Bioorg Med Chem Lett. 2016. PMID: 26821821
Discovery of acyl guanidine tryptophan hydroxylase-1 inhibitors.
Goldberg DR, De Lombaert S, Aiello R, Bourassa P, Barucci N, Zhang Q, Paralkar V, Stein AJ, Valentine J, Zavadoski W. Goldberg DR, et al. Among authors: bourassa p. Bioorg Med Chem Lett. 2016 Jun 15;26(12):2855-2860. doi: 10.1016/j.bmcl.2016.04.057. Epub 2016 Apr 21. Bioorg Med Chem Lett. 2016. PMID: 27146606
Optimization of spirocyclic proline tryptophan hydroxylase-1 inhibitors.
Goldberg DR, De Lombaert S, Aiello R, Bourassa P, Barucci N, Zhang Q, Paralkar V, Stein AJ, Holt M, Valentine J, Zavadoski W. Goldberg DR, et al. Among authors: bourassa p. Bioorg Med Chem Lett. 2017 Feb 1;27(3):413-419. doi: 10.1016/j.bmcl.2016.12.053. Epub 2016 Dec 23. Bioorg Med Chem Lett. 2017. PMID: 28041831
Investigation of SAMD1 ablation in mice.
Campbell B, Weber LM, Engle SJ, Ozolinš TRS, Bourassa P, Aiello R, Liefke R. Campbell B, et al. Among authors: bourassa p. Sci Rep. 2023 Feb 21;13(1):3000. doi: 10.1038/s41598-023-29779-3. Sci Rep. 2023. PMID: 36810619 Free PMC article.
Tumor-selective, antigen-independent delivery of a pH sensitive peptide-topoisomerase inhibitor conjugate suppresses tumor growth without systemic toxicity.
Gayle S, Aiello R, Leelatian N, Beckta JM, Bechtold J, Bourassa P, Csengery J, Maguire RJ, Marshall D, Sundaram RK, Van Doorn J, Jones K, Moore H, Lopresti-Morrow L, Paradis T, Tylaska L, Zhang Q, Visca H, Reshetnyak YK, Andreev OA, Engelman DM, Glazer PM, Bindra RS, Paralkar VM. Gayle S, et al. Among authors: bourassa p. NAR Cancer. 2021 Jun 4;3(2):zcab021. doi: 10.1093/narcan/zcab021. eCollection 2021 Jun. NAR Cancer. 2021. PMID: 34316708 Free PMC article.
Correction to 'Tumor-selective, antigen-independent delivery of a pH sensitive peptide-topoisomerase inhibitor conjugate suppresses tumor growth without systemic toxicity'.
Gayle S, Aiello R, Leelatian N, Beckta JM, Bechtold J, Bourassa P, Csengery J, Maguire RJ, Marshall D, Sundaram RK, Van Doorn J, Jones K, Moore H, Lopresti-Morrow L, Paradis T, Tylaska L, Zhang Q, Visca H, Reshetnyak YK, Andreev OA, Engelman DM, Glazer PM, Bindra RS, Paralkar VM. Gayle S, et al. Among authors: bourassa p. NAR Cancer. 2021 Dec 7;3(4):zcab047. doi: 10.1093/narcan/zcab047. eCollection 2021 Dec. NAR Cancer. 2021. PMID: 34888524 Free PMC article.
Lower GLUT1 and unchanged MCT1 in Alzheimer's disease cerebrovasculature.
Leclerc M, Tremblay C, Bourassa P, Schneider JA, Bennett DA, Calon F. Leclerc M, et al. Among authors: bourassa p. J Cereb Blood Flow Metab. 2024 Mar 5:271678X241237484. doi: 10.1177/0271678X241237484. Online ahead of print. J Cereb Blood Flow Metab. 2024. PMID: 38441044 Free article.
64 results